Gore Completes Acquisition of Conformal Medical

February 19, 2026—Gore & Associates announced it has completed its acquisition of Conformal Medical, developer of the investigational CLAAS AcuFORM System, a next-generation left atrial appendage occlusion (LAAO) technology.

The transaction expands Gore’s structural heart and endovascular portfolio, adding an investigational LAAO platform to its product development pipeline. The company notes that LAAO devices are used to reduce stroke risk in patients with nonvalvular atrial fibrillation who are seeking an alternative to long-term oral anticoagulation.

Under the terms of the deal, Conformal Medical will operate as a wholly owned subsidiary of Gore. The company stated that Conformal Medical’s focus will remain on advancing its investigational technology and conducting planned clinical studies.

“With this acquisition now complete, we are further strengthening Gore’s product development pipeline in endovascular treatment, with the goal of reaching more patients,” said Bret Snyder, board chair and CEO of Gore & Associates, in the release. “We are delighted to officially welcome Conformal Medical to our Enterprise.”

“Joining the Gore Enterprise represents an important next chapter for Conformal Medical,” added James Reinstein, President and CEO of Conformal Medical. “Gore’s experience in medical technology development and its commitment to innovation will enable us to benefit from their science-driven approach and long-time commitment to improving patient care.”